NASDAQ:ORTX

Orchard Therapeutics Stock Forecast, Price & News

$2.87

+0.02 (+0.70 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.80

▼

$2.95

50-Day Range

$2.85

▼

$5.34

52-Week Range

$2.80

▼

$9.08

Volume1.81 million shs

Average Volume607,280 shs

Market Capitalization$355.22 million

P/E RatioN/A

Dividend YieldN/A

Beta1.15

30 days | 90 days | 365 days | Advanced Chart

Receive ORTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Orchard Therapeutics

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Orchard Therapeutics plc (NASDAQ:ORTX) Short Interest Update
July 31, 2021 | americanbankingnews.com

Election 2021: Three candidates vying for Port Orchard Position 2 post
July 30, 2021 | msn.com

Popular Msia F&B chain Nam Heong to open new outlet at ION Orchard in August

Orchard Central Opens First Tesla V3 Supercharger Station In Southeast Asia
July 28, 2021 | msn.com

COVID-19 lockdowns lead to 93 per cent drop in sales at Glenbernie Orchard at Darkes Forest
July 26, 2021 | msn.com

ORTX Feb 2022 7.500 call
July 23, 2021 | ca.finance.yahoo.com

Wet summer brings record peach crop to Eckert’s Orchard
July 23, 2021 | msn.com

Frost, rain, and now heat: Murphy’s Orchard battles ‘triple threat’ of weather
July 23, 2021 | msn.com

Election 2021: Three candidates seek to fill open Port Orchard at-large council position
July 22, 2021 | msn.com

Global Orchard Type Tractor Market 2021 Trending Technologies, Developments, Key Players and End-use Industry to 2026
July 22, 2021 | marketwatch.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORTX
Previous Symbol
CUSIPN/A
CIK1748907
Webwww.orchard-tx.com
Phone011-44-0-203-3846700
Employees224
Year FoundedN/A

Sales & Book Value

Annual Sales$2.60 million
Price / Sales136.62
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.82 per share
Price / Book1.58

Profitability

EPS (Most Recent Fiscal Year)($1.53)
Net Income$-151,980,000.00
Net MarginsN/A
Return on Equity-60.17%
Return on Assets-42.59%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares123,770,000
Market Cap$355.22 million
Next Earnings Date8/5/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.98 out of 5 stars

Medical Sector

615th out of 2,220 stocks

Biological Products, Except Diagnostic Industry

86th out of 213 stocks

3.5 Analyst's Opinion

Consensus Rating
Orchard Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.75, Orchard Therapeutics has a forecasted upside of 379.1% from its current price of $2.87.
Amount of Analyst Coverage
Orchard Therapeutics has only been the subject of 3 research reports in the past 90 days.

4.1 Community Rank

Outperform Votes
Orchard Therapeutics has received 145 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Orchard Therapeutics has received 86 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Orchard Therapeutics has received 62.77% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote “Outperform” if you believe ORTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Orchard Therapeutics does not currently pay a dividend.
Dividend Growth
Orchard Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orchard Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.20% of the stock of Orchard Therapeutics is held by insiders.
Percentage Held by Institutions
63.04% of the stock of Orchard Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Orchard Therapeutics are expected to grow in the coming year, from ($1.34) to ($1.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Orchard Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Orchard Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Orchard Therapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions

Is Orchard Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Orchard Therapeutics stock.
View analyst ratings for Orchard Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Orchard Therapeutics?

Wall Street analysts have given Orchard Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orchard Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Orchard Therapeutics?

Orchard Therapeutics saw a decrease in short interest in July. As of July 15th, there was short interest totaling 3,640,000 shares, a decrease of 29.2% from the June 30th total of 5,140,000 shares. Based on an average trading volume of 497,400 shares, the days-to-cover ratio is presently 7.3 days. Approximately 3.2% of the company's shares are sold short.
View Orchard Therapeutics' Short Interest.

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Orchard Therapeutics.

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings data on Thursday, May, 13th. The company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02.
View Orchard Therapeutics' earnings history.

How has Orchard Therapeutics' stock been impacted by COVID-19?

Orchard Therapeutics' stock was trading at $9.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ORTX shares have decreased by 68.4% and is now trading at $2.87.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ORTX?

4 Wall Street analysts have issued 12-month target prices for Orchard Therapeutics' shares. Their forecasts range from $12.00 to $17.00. On average, they expect Orchard Therapeutics' stock price to reach $13.75 in the next year. This suggests a possible upside of 379.1% from the stock's current price.
View analysts' price targets for Orchard Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:

Dr. Bobby Gaspar Ph.D., M.D., CEO, Member of Scientific Advisory Board & Exec. Director (Age 56, Pay $712.41k)
Mr. Frank E. Thomas, Pres & COO (Age 51, Pay $586.18k)
Ms. Renee T. Leck, Director of Investor Relations
Mr. John Ilett, Chief of Staff, Chief Legal Officer & Company Sec.
Molly Cameron, Mang. of Corp. Communications
Mr. John Cerio, Chief Human Resource Officer
Dr. Anne Dupraz-Poiseau, Chief Devel. Officer
Mr. Adrien Lemoine, Chief Bus. Officer
Mr. Robin Kenselaar, Sr. VP & GM of EMEA Commercial Operations
Mr. Braden Parker, Chief Commercial Officer

Who are some of Orchard Therapeutics' key competitors?

Some companies that are related to Orchard Therapeutics include Immunocore (IMCR), BioAtla (BCAB), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), Ocugen (OCGN), Krystal Biotech (KRYS), AlloVir (ALVR), Graphite Bio (GRPH), Agenus (AGEN), Vaxcyte (PCVX), Monte Rosa Therapeutics (GLUE), Forma Therapeutics (FMTX), Inhibrx (INBX), Scholar Rock (SRRK) and Atara Biotherapeutics (ATRA).
View all of ORTX's competitors.

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $2.87.

How much money does Orchard Therapeutics make?

Orchard Therapeutics has a market capitalization of $355.22 million and generates $2.60 million in revenue each year. The company earns $-151,980,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 224 workers across the globe.

What is Orchard Therapeutics' official website?

The official website for Orchard Therapeutics is www.orchard-tx.com.

Where are Orchard Therapeutics' headquarters?

Orchard Therapeutics is headquartered at 108 CANNON STREET, LONDON X0, EC4N 6EU.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700.

This page was last updated on 8/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here